Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

36.47 -1.06 (-2.84%)
Streaming Delayed Price Updated: 12:17 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
32 33 Next >
TGT Stock Alert: Have Target’s Sales Numbers Peaked?
Target (TGT) stock is in hot water on Friday after Citi analyst Paul Lejuez warned investors to stay away from the retailer. 
Via InvestorPlace
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily
Wall Street Loves These 3 Growth Stocks -- Should You?
Analysts think all three of these stocks could soar. 
Via The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Can This Gene-Editing Stock Deliver 10X Returns?
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Wall Street is at max pessimism with this biotech, which might be a big mistake. 
Via The Motley Fool
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Today, CRISPR has reached an important turning point. 
Via The Motley Fool
Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock
Coinbase and the crypto industry at large is at war with regulators. But Cathie Wood is still buying shares of COIN stock. 
Via InvestorPlace
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. 
Via InvestorPlace
3 Disruptors I Love Right Now
These stocks could deliver huge returns as the companies transform the economy. 
Via The Motley Fool
CRISPR Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for CRISPR Therapeutics's Future
Via Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
The clinical-stage biotech company has been on the rise. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for June
These stocks have what it takes to deliver long-term growth. 
Via The Motley Fool
Prediction: These 2 Stocks Could Double In the Next Year
It would be a continuation of solid recent performances. 
Via The Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now
These stocks might not remain under $100 for too much longer. 
Via The Motley Fool
2 Supercharged Stocks to Buy With $100
These stocks are climbing in the double digits. 
Via The Motley Fool
2 Top Trends to Invest $5,000 in Right Now
Renewable energy and gene-editing medical therapies are poised to grow exponentially. 
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health
Both stocks are recovering after big losses last year. 
Via The Motley Fool
A Good Week For The Market But A Pause In The Biotech Rally
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It
Her investing thesis for holding it is probably the same as ever. 
Via The Motley Fool
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
2 Stocks You'll Be Glad You Bought at These Prices
Bear markets create opportunities to buy high-growth stocks at discounted valuations. 
Via The Motley Fool
2 Soaring Growth Stocks That Could Rocket Even Higher
One of these stocks is up 57% this year, and the other one has more than tripled already. 
Via The Motley Fool
Why These 3 Nasdaq Stocks Were Glowing Green This Week
These three biopharmaceutical stocks rocketed higher this week. 
Via The Motley Fool
Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG (NASDAQ: CRSP) reported strong 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.